Generic name: saxagliptin hydrochloride 5mg
Dosage form: tablet, film coated
Medically reviewed on April 19, 2018.
The recommended dosage of ONGLYZA is 2.5 mg or 5 mg once daily taken regardless of meals. ONGLYZA tablets must not be split or cut.
Dosage in Patients with Renal Impairment
No dosage adjustment for ONGLYZA is recommended for patients with eGFR ≥45mL/min/1.73 m2.
The dosage of ONGLYZA is 2.5 mg once daily (regardless of meals) for patients with eGFR <45mL/min1.73 m2 (which includes a subset of moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis) [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)]. ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis.
Because the dosage of ONGLYZA should be limited to 2.5 mg based upon renal function, assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.
Dosage Adjustment with Concomitant Use of Strong CYP3A4/5 Inhibitors
The dosage of ONGLYZA is 2.5 mg once daily when coadministered with strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin
When ONGLYZA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia [see Warnings and Precautions (5.3)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Onglyza (saxagliptin)
- Onglyza Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 13 Reviews
- Drug class: dipeptidyl peptidase 4 inhibitors
- FDA Alerts (3)